The contrast within Siemens’ sprawling industrial empire could hardly be starker. While Siemens Energy surged to a fresh all-time high of €191.66 on Friday after lifting its 2026 guidance, its med-tech sibling Siemens Healthineers plumbed depths not seen in a year. The Xetra session saw the stock close at €35.51 — precisely the 52-week trough — marking a fourth consecutive losing session that shaved roughly 1.7% off the share price.
That closing level sits a full 29% below the July 2025 peak of €49.86. The distance to the 200-day moving average, currently at €43.85, has ballooned to nearly 20%. Technical indicators paint a bleak picture: the relative strength index has dropped to 25.5, a reading that typically signals an oversold condition but has yet to trigger any meaningful reversal. Since the turn of the year, the stock has surrendered roughly a fifth of its value.
Nor is Siemens Healthineers suffering in isolation. Fresenius also logged its fourth straight down day on Friday, shedding around 1.25%, underscoring that the pressure on the healthcare and diagnostics sector is broad-based rather than company-specific.
A Clearer Path to Independence
Away from the daily price action, the long-awaited separation from parent Siemens AG is taking concrete shape. On Thursday, Siemens officially confirmed the timeline for divesting its remaining stake in Healthineers. The final shareholder vote on the transaction is scheduled for the annual general meeting in February 2027. Under the proposed structure, Siemens shareholders would receive Healthineers shares directly under Germany’s Umwandlungsgesetz conversion law. The company says regulatory preparations are already at an advanced stage.
Should investors sell immediately? Or is it worth buying Siemens Healthineers?
All Eyes on May 7
With the spin-off roadmap now public, the immediate catalyst for the stock shifts to operational performance. Management is due to report second-quarter figures on May 7. After a sluggish start to the fiscal year, the core imaging and diagnostics divisions face intense scrutiny. In the prior quarter, earnings per share slipped to €0.40 on revenue of €5.4 billion.
Analysts, however, remain notably unfazed by the technical weakness. RBC Capital Markets reaffirmed its “outperform” rating on the stock just this week. The consensus price target among banks stands at roughly €53, implying upside potential of nearly 50% from current levels.
For that gap to close, the upcoming earnings release will need to demonstrate a stabilization in operating margins. A convincing set of numbers could quickly narrow the valuation discount that has opened up. Market observers also expect the company to maintain its dividend trajectory, with forecasts pointing to a payout of €1.01 per share for the current fiscal year.
Whether the next directional signal comes from Healthineers’ own results or from competitor earnings in the med-tech space remains to be seen — but the stakes for the May 7 report could hardly be higher.
Ad
Siemens Healthineers Stock: Buy or Sell?! New Siemens Healthineers Analysis from April 25 delivers the answer:
The latest Siemens Healthineers figures speak for themselves: Urgent action needed for Siemens Healthineers investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 25.
Siemens Healthineers: Buy or sell? Read more here...
